MIT researchers created liver tissue systems that simulate fat accumulation, inflammation, and fibrosis seen in metabolic dysfunction-associated steatotic liver disease (MASLD), enabling more realistic study of disease progression than animal models. Published data validate the model's ability to reproduce key pathological and metabolic dysfunction states present in human patients.
The approach supports preclinical testing of drug candidates by capturing nuanced liver responses, including variable effects observed with existing treatments like resmetirom. This innovation might help identify targets and validate therapies more reliably for a condition affecting over 100 million Americans.
Source & further reading
New tissue models could help researchers develop drugs for liver disease ↗Source published 2026-02-03. This report was prepared with AI assistance from the linked primary-source material. Claims and limitations should be checked against the original announcement or research.